A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers

Documents similaires

• Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
  par: William K. Schmidt, et autres
  Publié: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
  par: Kyoko Miyamoto, et autres
  Publié: (2024)
• Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
  par: Guihong Yang, et autres
  Publié: (2024)
• Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”
  Publié: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
  par: Tianxing Liu, et autres
  Publié: (2024)